Compare Ginkgo Bioworks Holdings Inc (DNA) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

REMX, the VanEck Rare Earth and Strategic Metals ETF, trades at $77.52, down 1.19% today. The technical outlook is bullish based on moving averages, with a neutral oscillator reading. Recent news highlights U.S. efforts to build rare earth supply chain independence, with construction starting on Energy Fuels' Utah plant expansion (Forbes, 2026-08-04). The ETF provides exposure to 38 global rare earth companies but exhibits high volatility (~50% annualized) and turnover.

The long-term outlook for REMX is supported by geopolitical shifts and demand for critical minerals in technology and defense. However, risks include high volatility, China's dominance in the sector, and sensitivity to trade policies. Investors should weigh the growth potential against the ETF's speculative nature and lack of traditional fundamental metrics like P/E or P/S ratios.